| dc.contributor.author | Viswanathan, Meera et al. | |
| dc.date.accessioned | 2021-04-26T17:51:30Z | |
| dc.date.available | 2021-04-26T17:51:30Z | |
| dc.date.issued | 2020 | |
| dc.identifier.uri | https://doi.org/10.1002/14651858.CD013718 | en_US |
| dc.identifier.uri | https://hdl.handle.net/20.500.12663/2600 | |
| dc.description.abstract | Background: Coronavirus disease 2019 (COVID-19) is caused by the novel betacoronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Most people infected with SARS-CoV-2 have mild disease with unspecific symptoms, but about 5% become critically ill withrespiratory failure, septic shock and multiple organ failure. An unknown proportion of infected individuals never experience COVID-19symptoms although they are infectious, that is, they remain asymptomatic. Those who develop the disease, go through a presymptomaticperiod during which they are infectious. Universal screening for SARS-CoV-2 infections to detect individuals who are infected before theypresent clinically, could therefore be an important measure to contain the spread of the disease. | en_US |
| dc.language | English | en_US |
| dc.subject | Severe Acute Respiratory Syndrome | en_US |
| dc.subject | SARS-CoV-2 | en_US |
| dc.subject | Systematic Review | en_US |
| dc.subject | Coronavirus Infections | en_US |
| dc.title | Universal screening for SARS‐CoV‐2 infection: a rapid review | en_US |
| eihealth.country | Others | en_US |
| eihealth.category | Public Health Interventions | en_US |
| eihealth.type | Published Article | en_US |
| eihealth.maincategory | Slow Spread / Reducir la Dispersión | en_US |
| dc.relation.ispartofjournal | Cochrane Database Syst Rev | en_US |
